CXCL5 and diabetes mellitus: The most interesting feature ofthis newly identified target is that is directed not only for insulinresistance treatment, but could also target diabetes-associated co-morbidities.It is interesting to notice, at some extent, similarities between otherinsulin-sensitizing drugs, such as metformin and anti-CXCL5 therapy.